Lurbinectedin in Small Cell Lung Cancer .

By Matthew Stenger // Posted: 6/4/2020

As Reported in The Lancet Oncology by Trigo et al, Second-Line Treatment with the Selective Oncogenic Transcription Inhibitor Lurbinectedin showed Activity in Patients with Small Cell lung Cáncer included in a Phase II Basket trial.

The Trial Includes Cohorts Representing nine Different Tumor Types.